Basal Insulin Initiation and Maintenance in Adults with Type 2 Diabetes Mellitus in the United States.
basal insulin
medication persistence
patient survey
type 2 diabetes mellitus
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
11
2019
accepted:
09
02
2020
entrez:
21
4
2020
pubmed:
21
4
2020
medline:
21
4
2020
Statut:
epublish
Résumé
A survey of US adults with type 2 diabetes mellitus was conducted to better understand patients' insulin initiation experiences and treatment persistence behaviors. Participants were recruited from consumer panels and grouped by basal insulin treatment pattern: continuers (no gap of ≥7 days within 6 months of initiation); interrupters (gap ≥7 days, resumed treatment); discontinuers (stopped for ≥7 days, not resumed). A quota of approximately 50 respondents per persistence category was set. A total of 154 respondents (52 continuers, 52 interrupters, 50 discontinuers) completed the survey. Mean age was 51.4 years; 51.9% male. Continuers were more likely to report their views being considered during initiation, and less likely to report a sense of failure. Concerns included insulin dependence (64.3% agree/strongly agree), frequent blood glucose monitoring (55.2%), costs/ability to pay (53.9%), fears of or mistakes during self-injection (52.6%), and weight gain (52.6%). Continuers were motivated by benefits of insulin therapy; experienced or potential side effects were notable factors for interruption/discontinuation. Healthcare provider instruction was indicated as a reason for continuing, stopping, and restarting therapy. Benefits of basal insulin therapy motivated continuers while side effects impacted interruption/discontinuation. Persistence on basal insulin is often influenced by provider actions. Earlier provider intervention upon signs of treatment discontinuation may promote persistence.
Identifiants
pubmed: 32308452
doi: 10.2147/DMSO.S237948
pii: 237948
pmc: PMC7140903
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1023-1033Informations de copyright
© 2020 Kalirai et al.
Déclaration de conflit d'intérêts
Kalirai was an employee of Eli Lilly and Company at the time the study was conducted. Perez-Nieves, Hadjiyianni, Pollom, and Reed are employees and stock holders of Eli Lilly and Company. Stephenson and Grabner are employees of HealthCore, Inc. Geremakis was an employee of HealthCore, Inc. at the time the study was conducted. Ivanova was an employee of Analysis Group, Inc. at the time the study was conducted. Fisher is a consultant to Eli Lilly and Company. The authors report no other conflicts of interest in this work.
Références
Patient Prefer Adherence. 2010 Jun 24;4:147-56
pubmed: 20622915
Diabet Med. 2013 May;30(5):512-24
pubmed: 23323988
Health Aff (Millwood). 2013 Feb;32(2):223-31
pubmed: 23381514
Adv Ther. 2013 Dec;30(12):1128-40
pubmed: 24293131
Diabetes Care. 2012 Nov;35(11):2393-401
pubmed: 22995096
Diabetes Care. 2015 Jan;38(1):140-9
pubmed: 25538310
Hippokratia. 2014 Oct-Dec;18(4):306-9
pubmed: 26052195
Diabetes Educ. 2004 Mar-Apr;30(2):274-80
pubmed: 15095517
J Adv Nurs. 2006 Apr;54(2):151-8
pubmed: 16553701
Diabetes Ther. 2014 Jun;5(1):225-42
pubmed: 24782063
Am J Manag Care. 2008 Feb;14(2):71-5
pubmed: 18269302
Diabet Med. 2012 May;29(5):682-9
pubmed: 22313123
Clinicoecon Outcomes Res. 2013 Oct 03;5:497-505
pubmed: 24124384
Diabetes Care. 2014 Apr;37(4):985-92
pubmed: 24198301
Clin Diabetes. 2017 Jan;35(1):35-42
pubmed: 28144044
J Am Osteopath Assoc. 2013 Feb;113(2):152-62
pubmed: 23412677
MedGenMed. 2005 Mar 16;7(1):4
pubmed: 16369309
Diabet Med. 2012 Jul;29(7):e13-20
pubmed: 22268988
Curr Med Res Opin. 2013 Sep;29(9):1083-91
pubmed: 23734906
BMJ Open. 2013 Apr 30;3(4):
pubmed: 23633415
Prim Care Diabetes. 2018 Apr;12(2):155-162
pubmed: 29100717
Curr Med Res Opin. 2016;32(4):669-80
pubmed: 26703951
Curr Med Res Opin. 2016 Sep;32(9):1465-75
pubmed: 26907851
Diabetes Care. 2008 Jan;31 Suppl 1:S97-104
pubmed: 18165344
BMJ. 2006 Jul 1;333(7557):15
pubmed: 16790458
Endocr Pract. 2014 Jan;20(1):52-61
pubmed: 24013990
Diabetes Ther. 2013 Dec;4(2):175-94
pubmed: 23990497
Diabetes Educ. 2013 Jul-Aug;39(4):560-7
pubmed: 23771842
Curr Med Res Opin. 2009 Mar;25(3):691-700
pubmed: 19196223
Patient Prefer Adherence. 2016 Jul 22;10:1299-307
pubmed: 27524885
J Multidiscip Healthc. 2014 Jul 02;7:267-82
pubmed: 25061317
Diabetes Care. 2012 Jun;35(6):1364-79
pubmed: 22517736
Diabetes Care. 2017 Jan;40(Suppl 1):S4-S5
pubmed: 27979887
Curr Med Res Opin. 2010 Jan;26(1):231-8
pubmed: 19921965
Curr Med Res Opin. 2007 Dec;23(12):3105-12
pubmed: 17977482
Curr Med Res Opin. 2017 Oct;33(10):1843-1851
pubmed: 28604112
Patient Educ Couns. 2005 May;57(2):153-7
pubmed: 15911187
Curr Med Res Opin. 2011 Jun;27(6):1169-74
pubmed: 21469914
Prim Care Diabetes. 2010 Apr;4 Suppl 1:S11-8
pubmed: 20394886
Curr Med Res Opin. 2017 Oct;33(10):1833-1842
pubmed: 28604111
Diabetes Care. 2005 Oct;28(10):2543-5
pubmed: 16186296
Mayo Clin Proc. 2011 Apr;86(4):304-14
pubmed: 21389250
PLoS One. 2012;7(6):e36361
pubmed: 22719830